Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus LEUPROLIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus LEUPROLIDE ACETATE.
FACTREL vs LEUPROLIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Upon continuous administration, it suppresses pituitary gonadotropin secretion by downregulating GnRH receptors, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and consequently reducing sex steroid (testosterone and estrogen) production in the gonads.
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
Prostate cancer: 7.5 mg IM once monthly or 22.5 mg IM once every 3 months or 45 mg SC once every 6 months. Central precocious puberty: 50 mcg/kg/day SC or 7.5 mg IM once monthly. Endometriosis: 3.75 mg IM once monthly or 11.25 mg IM once every 3 months.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
Terminal elimination half-life is approximately 3 hours following intravenous administration; after subcutaneous depot formulations, the effective half-life is extended due to slow release, with a terminal half-life of about 3-4 weeks for the 1-month depot.
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Renal: approximately 5% as unchanged drug; hepatic metabolism accounts for the majority of clearance, with metabolites excreted renally and fecally; biliary excretion is minimal.
Category C
Category D/X
GnRH Agonist
GnRH Agonist